Lanzhou Univ. BRD4 compound 21r

Lanzhou Univ. BRD4 compound 21r: sourced facts only. name: "All the results showed that compound 21r was a potent BRD4 inhibitor with BD1 selectivity, which had potential in treatment of leukemia." [PMID:38749341]; target: "All the results showed that compound 21r was a potent BRD4 inhibitor with BD1 selectivity, which had potential in treatment of leukemia." [PMID:38749341]; developer: "School of Pharmacy & Collaborative Innovation Center for Northwestern Chinese Medicine, Lanzhou University, Lanzhou 730000, China." [PMID:38749341]; stage: "Further studies revealed that 21r inhibited proliferation by decreasing the expression of proto-oncogene c-Myc, blocking cell cycle in G0/G1 phase, and inducing apoptosis in MV-4-11 cells in a dose-dependent manner." [PMID:38749341]